AU2016368317B2 - Inhibitors of influenza virus replication, application methods and uses thereof - Google Patents

Inhibitors of influenza virus replication, application methods and uses thereof Download PDF

Info

Publication number
AU2016368317B2
AU2016368317B2 AU2016368317A AU2016368317A AU2016368317B2 AU 2016368317 B2 AU2016368317 B2 AU 2016368317B2 AU 2016368317 A AU2016368317 A AU 2016368317A AU 2016368317 A AU2016368317 A AU 2016368317A AU 2016368317 B2 AU2016368317 B2 AU 2016368317B2
Authority
AU
Australia
Prior art keywords
alkylene
membered
mmol
compound
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016368317A
Other languages
English (en)
Other versions
AU2016368317A1 (en
Inventor
Xiaohong Lin
Qingyun REN
Changhua TANG
Kai YI
Junjun YIN
Yingjun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2016368317A1 publication Critical patent/AU2016368317A1/en
Application granted granted Critical
Publication of AU2016368317B2 publication Critical patent/AU2016368317B2/en
Assigned to NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED reassignment NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED Request for Assignment Assignors: SUNSHINE LAKE PHARMA CO., LTD.
Assigned to SUNSHINE LAKE PHARMA CO., LTD. reassignment SUNSHINE LAKE PHARMA CO., LTD. Request for Assignment Assignors: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016368317A 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof Active AU2016368317B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510908329.2 2015-12-09
CN201510908329 2015-12-09
PCT/CN2016/109079 WO2017097234A1 (en) 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof

Publications (2)

Publication Number Publication Date
AU2016368317A1 AU2016368317A1 (en) 2018-06-07
AU2016368317B2 true AU2016368317B2 (en) 2019-05-23

Family

ID=59012608

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016368317A Active AU2016368317B2 (en) 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof

Country Status (9)

Country Link
US (2) US10717732B2 (enExample)
EP (1) EP3362451B1 (enExample)
JP (1) JP6952695B2 (enExample)
KR (1) KR102671350B1 (enExample)
CN (2) CN109748915B (enExample)
AU (1) AU2016368317B2 (enExample)
RU (1) RU2737190C2 (enExample)
SG (1) SG11201804225PA (enExample)
WO (1) WO2017097234A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109071567B (zh) * 2016-05-19 2021-03-23 四川大学 抗流感小分子化合物及其制备方法和用途
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
RU2727772C1 (ru) * 2016-09-05 2020-07-23 Гуандун Рэйновент Байотек Ко., Лтд. Производные пиримидина против вируса гриппа
WO2018108125A1 (en) 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
ES2901875T3 (es) 2017-04-24 2022-03-24 Cocrystal Pharma Inc Derivados de la pirrolopirimidina útiles como inhibidores de la replicación del virus de la influenza
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
KR20200130287A (ko) * 2018-02-08 2020-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
NZ767352A (en) * 2018-03-05 2023-05-26 Guangdong Raynovent Biotech Co Ltd Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
WO2021057881A1 (zh) * 2019-09-27 2021-04-01 广东东阳光药业有限公司 一种奥司他韦制剂
CN110967239B (zh) * 2020-01-02 2022-05-10 国家地质实验测试中心 一种金属铬溶解氧化方法
US20230265107A1 (en) * 2020-07-10 2023-08-24 Sichuan Haisco Pharmaceutical Co., Ltd. Pb2 inhibitor, and preparation method therefor and use thereof
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US20250289826A1 (en) * 2022-04-29 2025-09-18 Tsinghua University Plpro protein inhibitor, and preparation method and application thereof
WO2026016541A1 (zh) * 2024-07-16 2026-01-22 武汉武药科技有限公司 一种新型抗病毒化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073481A1 (en) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
DK2442809T3 (en) * 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR20130128435A (ko) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CN103492382A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
NZ714502A (en) * 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3068434A1 (en) 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
EP3068776B1 (en) * 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
SG11201700956VA (en) 2014-08-08 2017-03-30 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
MX2017002972A (es) 2014-09-08 2017-05-30 Janssen Sciences Ireland Uc Pirrolopirimidinas para usarse en la infeccion por el virus de la gripe.
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073481A1 (en) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOYD, MICHAEL J. et al., Bioorganic & Medicinal Chemistry Letters, (2015-03-14), vol. 25, pages 1990 - 1994 *

Also Published As

Publication number Publication date
US10717732B2 (en) 2020-07-21
JP6952695B2 (ja) 2021-10-20
JP2018536681A (ja) 2018-12-13
RU2737190C2 (ru) 2020-11-25
US20180346463A1 (en) 2018-12-06
US11225477B2 (en) 2022-01-18
RU2018124993A (ru) 2020-01-14
AU2016368317A1 (en) 2018-06-07
EP3362451B1 (en) 2023-04-12
US20200299294A1 (en) 2020-09-24
HK1254668A1 (en) 2019-07-26
KR102671350B1 (ko) 2024-05-30
WO2017097234A1 (en) 2017-06-15
SG11201804225PA (en) 2018-06-28
CN106854205A (zh) 2017-06-16
CA3005921A1 (en) 2017-06-15
EP3362451A1 (en) 2018-08-22
EP3362451A4 (en) 2019-07-03
CN109748915A (zh) 2019-05-14
CN109748915B (zh) 2021-03-26
RU2018124993A3 (enExample) 2020-02-05
CN106854205B (zh) 2019-07-09
KR20180088466A (ko) 2018-08-03

Similar Documents

Publication Publication Date Title
US11225477B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
US10647693B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
AU2017376541B2 (en) Inhibitors of influenza virus replication and uses thereof
US10501444B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
US11098042B2 (en) Inhibitors of influenza virus replication and uses thereof
AU2018331172A1 (en) Influenza virus replication inhibitor and use thereof
CN108727369B (zh) 流感病毒复制抑制剂及其用途
US10927118B2 (en) Inhibitors of influenza virus replication and uses thereof
CN110117285A (zh) 流感病毒复制抑制剂及其用途
CA3005921C (en) Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication
HK1254668B (en) Inhibitors of influenza virus replication, application methods and uses thereof
HK40011744B (en) Inhibitors of influenza virus replication and uses thereof
HK40011744A (en) Inhibitors of influenza virus replication and uses thereof
HK40002434A (en) Inhibitors of influenza virus replication, application methods and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY

Free format text: FORMER OWNER(S): SUNSHINE LAKE PHARMA CO., LTD.

PC Assignment registered

Owner name: SUNSHINE LAKE PHARMA CO., LTD.

Free format text: FORMER OWNER(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED